Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06602193 · ClinicalTrials.gov registry record · Phase 2

Safety and Pharmacodynamic Effects of BIIB122 in Participants With LRRK2-Associated Parkinson's Disease (LRRK2-PD)

A Phase 2 study of Parkinson Disease, sponsored by Denali Therapeutics.

Recruiting
Registry status
Phase 2
Development phase
50
Enrollment target
20
Study locations

NCT06602193 is a Phase 2 study of Parkinson Disease that is actively recruiting participants, run by Denali Therapeutics. The registered enrollment target is 50 participants, below the 5,326-participant average among 297 other Parkinson Disease trials with a reported enrollment target (99% lower). The trial reports 20 study locations across 6 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06602193, a Phase 2 study of Parkinson Disease, is actively recruiting participants, sponsored by Denali Therapeutics.

RECRUITING
Registry status
Phase 2
Development phase
50 participants
Enrollment target
20
Study locations

Study Summary

This Phase 2a, multicenter, randomized, 12-week double-blind, placebo-controlled, parallel-group study, followed by an OLE, is designed to evaluate the safety, tolerability, and pharmacodynamic effects of BIIB122 in participants with LRRK2-PD. LRRK2-PD is defined as Parkinson's Disease (PD) in individuals who are heterozygous or homozygous carriers of a pathogenic LRRK2 variant that increases LRRK2 kinase activity.

Conditions Studied

Parkinson Disease

Interventions

  • DRUG BIIB122 225 mg
  • OTHER BIIB122-Matching Placebo

Study Locations (20)

Other

  • Technische Universität Dresden - Dresden
  • University of Lübeck - Lübeck
  • University Hospital Tübingen - Tübingen
  • Rabin Medical Center - Petah Tikva
  • Movement Disorders Institute, Sheba Medical Center - Ramat Gan
  • Tel Aviv Medical Center - Tel Aviv
  • Hospital Clinic de Barcelona - Barcelona
  • Hospital Universitari General de Catalunya - Barcelona
  • Hospital Universitari Vall d'Hebron - Barcelona
  • Hospital Universitario Donostia - Donostia / San Sebastian
  • Universitary Hospital La Princesa - Madrid
  • IDIVAL/University Hospital Marques de Valdecilla - Santander
  • Hospital Universitario Virgen del Rocio - Seville

California

  • Cedars-Sinai Department of Neurology - Los Angeles
  • University of California San Francisco - San Francisco

Washington

  • Evergreen Health Laboratory - Kirkland
  • Inland Northwest Research - Spokane

Florida

  • Parkinson's Disease and Movement Disorders Center - Boca Raton

Massachusetts

  • Beth Israel Deaconess Medical Center - Boston

New York

  • Ichan School of Medicine at Mount Sinai/Beth Israel Downtown-Movement Disorder Center - New York

Trial Details

FieldValue
Enrollment Target 50 participants
Start Date 2024-10-24
Est. Completion 2028-02-28
Phase Phase 2

Sponsor

Denali Therapeutics

12 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06602193

The ClinicalTrials.gov registry entry for NCT06602193 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 5,326-participant average among 297 other Parkinson Disease trials with a reported enrollment target (99% lower). The listed sponsor is Denali Therapeutics, which has 12 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Parkinson Disease appearing as the primary indexed condition, and to 2 interventions - of which BIIB122 225 mg is the first listed.

NCT06602193 reports 20 study locations spanning 6 distinct geographic areas - top geographies include Other, California, Washington.

Frequently Asked Questions

What is clinical trial NCT06602193 about?

NCT06602193 is a clinical study titled "Safety and Pharmacodynamic Effects of BIIB122 in Participants With LRRK2-Associated Parkinson's Disease (LRRK2-PD)". This Phase 2a, multicenter, randomized, 12-week double-blind, placebo-controlled, parallel-group study, followed by an OLE, is designed to evaluate the safety, tolerability, and pharmacodynamic effects of BIIB122 in participants with LRRK2-PD. LRRK2-PD is defined as Parkinson's Disease (PD) in indiv...

What is the current status of trial NCT06602193?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 50 participants. The study started on 2024-10-24. Estimated completion is 2028-02-28.

What conditions does trial NCT06602193 study?

This clinical trial studies the following conditions: Parkinson Disease.

What interventions are being tested in trial NCT06602193?

The interventions under investigation include: BIIB122 225 mg (DRUG), BIIB122-Matching Placebo (OTHER).

Who is sponsoring clinical trial NCT06602193?

This trial is sponsored by Denali Therapeutics, which has 12 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06602193 being conducted?

This trial has 20 study locations across California, Florida, Massachusetts, New York, Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Parkinson Disease

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Parkinson Disease

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.